ASCO 2015

 
 
 

The 2015 ASCO Annual Meeting took place May 29th through June 2nd in Chicago, Illinois.

 

Panobinostat combos can treat rel/ref MM

Mark Fuerst Read Article
Published: 06/13/15

ASCO2015_RodneyWhite_230.jpg
Crowd at ASCO 2015
©ASCO/Rodney White

Combination regimens including the histone deacetylase inhibitor panobinostat can produce durable responses and prolong progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM), according to research presented at the 2015 ASCO Annual Meeting. In a phase 2 trial, panobinostat plus lenalidomide and dexamethasone produced durable responses, even in high-risk, lenalidomide-refractory MM patients.  [Read Article]

CAR T-cell therapy seems feasible for NHL, MM

Mark Fuerst Read Article
Published: 06/11/15

ASCO2015_crowd_Rodney_White_230.jpg
Attendees at ASCO 2015
©ASCO/Rodney White

The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin lymphoma (NHL) and may be a feasible treatment option for multiple myeloma (MM) as well, according to researchers. In an ongoing phase 2 trial, CTL019 has produced durable responses in patients with relapsed or refractory NHL. And early results of a phase 1 trial suggest CTL019 can provide clinical benefit in heavily pretreated patients with MM. [Read Article]

A better FLT3 inhibitor for AML?

Jen Smith Read Article
Published: 06/10/15

ASCO215_attendees_talk_Scott_Morgan_230.jpg
Attendees at ASCO 2015
© ASCO/Scott Morgan

A dual inhibitor of FLT3 and Axl may produce more durable responses than other FLT3 inhibitors and improve survival in patients with FLT3-positive, relapsed or refractory acute myeloid leukemia (AML), according to a speaker at the 2015 ASCO Annual Meeting. The FLT3/Axl inhibitor, ASP2215, has not been compared against other FLT3 inhibitors directly, and the data presented were from a phase 1/2 study. However, the speaker said ASP2115 . . . [Read Article]

BCL-2 inhibitor shows potential for treating MM

HT Staff Read Article
Published: 06/07/15

ASCO2015_directions_Zach_Boyden-Holmes_220.jpg
Staff member giving directions
to an attendee at ASCO 2015
© ASCO/Zach Boyden-Holmes

A BCL-2 inhibitor that has shown activity in patients with chronic and acute leukemias could be a feasible treatment option for multiple myeloma (MM) too, according to research presented at the 2015 ASCO Annual Meeting. In a pair of phase 1 studies, the drug, venetoclax, prompted responses in certain patients with relapsed or refractory MM, both when given alone and in combination with bortezomib and dexamethasone. [Read Article]

CAR produces high CR rate in adults with rel/ref ALL

Jen Smith Read Article
Published: 06/06/15

ASCO2015_session_ipad_Max_Gersh_220.jpg
Audience during a session at 
the 2015 ASCO Annual Meeting
© ASCO/Max Gersh

A CD19-targeted chimeric antigen receptor (CAR) T-cell therapy can provide durable complete responses (CRs) or a bridge to allogeneic transplant in adults with relapsed or refractory acute lymphoblastic leukemia (ALL), updated results of a phase 1 study suggest. The therapy, JCAR015, produced a CR rate of 87%, and 33% of these patients went on to transplant. The median duration of response or relapse-free survival was 5.3 months.  [Read Article]

No survival difference with allo- or auto-SCT in PTCL

Jen Smith Read Article
Published: 06/05/15

ASCO2015_stairs_Max_Gersh_230.jpg
Attendees at ASCO 2015
© ASCO/Max Gersh

Allogeneic and autologous transplants produce similar survival rates when used as first-line therapy in younger patients with peripheral T-cell lymphoma (PTCL), according to interim results of the AATT trial. The study also showed that deaths among patients who received autologous stem cell transplants (auto-SCTs) were a result of relapse and salvage treatment, while deaths among allogeneic SCT (allo-SCT) recipients were transplant-related. [Read Article]

Triplet shows early promise for relapsed CLL, NHL

Jen Smith Read Article
Published: 06/05/15

ASCO2015_RodneyWhite_230.jpg
Crowd at ASCO 2015
©ASCO/Rodney White

A 3-drug combination is safe and highly active in certain patients with relapsed B-cell malignancies, according to a speaker at the 2015 ASCO Annual Meeting. The combination consists of the anti-CD20 monoclonal antibody ublituximab, the PI3Kδ inhibitor TGR-1202, and the BTK inhibitor ibrutinib. In a small, phase 1 study, the triplet produced an overall response rate of 62%. It was particularly active in patients with . . . [Read Article]

LSC phenotypes correlate with prognosis in AML

Jen Smith Read Article
Published: 06/04/15

ASCO2015_crowd_Rodney_White_230.jpg
Crowd at ASCO 2015
© ASCO/Rodney White

Researchers say they have identified 3 leukemia stem cell (LSC) phenotypes that are correlated with cytogenetic/molecular abnormalities and prognosis in acute myeloid leukemia (AML). The investigators believe this knowledge could aid risk stratification of AML patients, particularly those without identifiable risk factors. The findings may also pave the way for scientists to identify novel therapeutic targets on LSCs and monitor LSCs in response to therapy. [Read Article]

Single agent can treat resistant MM

HT Staff Read Article
Published: 06/03/15

lonial-sagar_ASCO15_Todd_Buchanan_230.jpg
Sagar Lonial, MD
© ASCO/Todd Buchanan

The anti-CD38 monoclonal antibody daratumumab can be effective as a stand-alone therapy for some heavily pretreated patients with multiple myeloma (MM), results of an ongoing phase 2 trial suggest. The study, known as SIRIUS or MMY2002, included more than 100 patients who had received 3 or more prior lines of therapy. Roughly 30% of these subjects responded to daratumumab, with a median response duration of about 7 months. [Read Article]

Drug prolongs PFS in indolent, refractory NHL

HT Staff Read Article
Published: 06/02/15

ASCO2015_info_strt_230.jpg
Inside McCormick Place, site of
the 2015 ASCO Annual Meeting

Adding obinutuzumab to treatment with bendamustine improves progression-free survival (PFS) in patients with rituximab-refractory, indolent non-Hodgkin lymphoma (NHL), interim results of the phase 3 GADOLIN trial suggest. Study investigators said patients who received obinutuzumab and bendamustine followed by obinutuzumab maintenance had roughly double the PFS of patients who received bendamustine alone. [Read Article]

Inhibitor may fulfill unmet need in MF

HT Staff Read Article
Published: 06/01/15

mesa-ruben-ASCO15_Zach_Boyden-Holmes_230.jpg
Ruben Mesa, MD
© ASCO/Zach Boyden-Holmes

The JAK2/FLT3 inhibitor pacritinib may fulfill an unmet need in the treatment of myelofibrosis (MF), according to a speaker at the 2015 ASCO Annual Meeting. Results of the phase 3 PERSIST-1 trial indicate that pacritinib is safe and effective for MF patients with thrombocytopenia. “Thrombocytopenia is a common feature in people with advanced [MF], and current treatment options have not been able to concurrently improve splenomegaly symptoms and cytopenias . . . [Read Article]

Drug improves upon standard therapy for relapsed CLL/SLL, speaker says

HT Staff Read Article
Published: 05/31/15

Chanan-Khan_Asher_Alban_Akmal_ASCO15_Zach_Boyden-Holmes_220.jpg
Asher Alban Akmal
Chanan-Khan, MD
© ASCO/Zach Boyden-Holmes

Interim results of the phase 3 HELIOS trial suggest that adding ibrutinib to treatment with bendamustine and rituximab (BR) improves outcomes for patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients who received ibrutinib and BR had significantly higher response rates and a significantly longer progression-free survival than patients who received BR with placebo. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}